Resumen

SIACHOQUE, Heber et al. Determination Of Interleukine-10 In Cancer Patients In Stages Iii And Iv Treated With Dexamethasone. Rev. Cienc. Salud [online]. 2005, vol.3, n.2, pp.148-155. ISSN 1692-7273.

Dexamethasone treatment in patients with cancer in stages III and IV is associated with immune response suppression, possibly because of the inhibiting effect produced by antigen presenting dendritic cells. Under dexamethasone action, dendritic cells secrete very low levels of IL-10 that not only diminish the Th2 lymphocyte response but also the one induced by NK cells. In most of experimental models, IL-10 levels increase when patients have been previously treated with dexamethasone, which inhibits the Th1 lymphocytes response and produces worsening sening of the process. Methodology: ELISA test was used to determine IL-10 in patients with different tumors in stages III and IV treated with chemotherapy and dexamethasone-metoclopramide and in healthy controls. Results: In the experimental model, all patients with cancer in stages III and IV exhibited very low levels of IL- 10, compared to those of the control group. In addition, IL-10 concentration did not increase in patients treated with dexamethasone. Our results show that IL-10 does not produce dendritic cells anergy nor cytotoxic response mediated by Th1 lymphocytes. Conclusion: it is possible that immune response suppression in this type of patients is the result of dexamethasone and not of IL-10 effect.

Palabras clave : Interleukin-10; neoplasms; glucocorticoids; dexamethasone; immunosuppression; dendritic cells.

        · resumen en Español     · texto en Español     · Español ( pdf )